Avanir's involuntary emotion drug approved by the FDA.

Avanir Inc. will produce an invonuntary emotion drug that was just approved by the FDA.
This is the first product to treat the pseudobulbar affect, and it is predicted to reach annual sales up to $500 million. The companies shares rose 15 percent.
Nuedexta is the first drug approved for the treatment of the little known, but not that rare, condition called pseudobulbar affect (PBA), which is also known as involuntary emotional expression disorder.